<DOC>
	<DOCNO>NCT02499978</DOCNO>
	<brief_summary>This clinical research study see switch Darunavir/Cobicistat ( ( PREZCOBIX™ , DRV/COBI ) Dolutegrivir ( Tivicay® , DTG ) HIV-infected individual undetectable HIV viral load nucleos ( ) ide reverse transcriptase inhibitor ( NRTI ) -containing therapy effective maintain virologic suppression 48 week treatment .</brief_summary>
	<brief_title>Darunavir/Cobicistat Dolutegravir Maintain Virologic Suppression Reduce NRTI-associated Toxicity</brief_title>
	<detailed_description>NRTIs stalwart treatment pre- post-ART era . However , NRTIs numerous toxicity partly due fact analog naturally occur nucleotide interfere activity numerous cellular function . In highly treatment-experienced individual two active drug salvage regimen , NRTI-sparing regimen show non-inferior NRTI-containing regimen [ 33 ] . However , study NRTI-sparing regimen consist two active medication generally disappoint . One limitation earlier NRTI-sparing regimen higher pill burden standard regimen . However , approval DTG co-formulated DRV/COBI , well-established antiviral activity , may allow compact , effective , NRTI-sparing regimen . A switch DTG/DRV/COBI virologically suppress HIV-infected individual potential avoid NRTI-associated toxicity maintain virologic suppression .</detailed_description>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>1 . HIV1 infection , document licensed ELISA test kit confirm Western blot time prior study entry . A second antibody test method ELISA acceptable alternative confirmatory test previous detectable HIV RNA level . 2 .Age ≥ 18 year 3 . HIV1 RNA &lt; 50 copies/mL stable antiretroviral regimen least 6 month prior study entry exclude blip ( i.e. , single measurement &lt; 200 copies/mL precede follow measurement &lt; 50 copies/mL ) 4 . At screen , patient stable antiretroviral regimen contain least one NRTI PI , NNRTI , INSTI 5 . No change antiretroviral regimen six month prior screen ( except switch coformulated tablet component tablet ) 6 . A desire switch current antiretroviral therapy due : ) Renal dysfunction ( microalbuminuria/proteinuria CrCl &lt; 70 mL/min/1.73 m2 ) tenofovir disoproxil fumarate ( TDF ) tenofovir al ; b ) Osteopenia osteoporosis TDFcontaining regimen ( i.e. , low Tscore ≥1.0 standard deviation young adult mean measure dualenergy xray absorptiometry ) ; c ) Peripheral neuropathy lipoatrophy least partially attributable ongoing NRTI use ; ) Intermediate high Framingham risk ( i.e. , ≥10 % 10year risk ) abacavircontaining regimen ; e ) Patient preference . 7 . Laboratory value within six month screen visit Hemoglobin ≥8.0 g/dL Platelet count ≥40,000/mm3 AST , ALT , alkaline phosphatase ≤5 × ULN Total bilirubin ≤2.5 x ULN ( except atazanavircontaining regimen ) Calculated creatinine clearance ( CrCl ) ≥45 mL/min estimate CockcroftGault equation : For men , ( 140 age year ) x ( body weight kg ) ÷ ( serum creatinine mg/dL x 72 ) = CrCl ( mL/min ) * *For woman , multiply result 0.85 = CrCl ( mL/min ) 8 . For woman reproductive potential , negative serum urine pregnancy test screen negative urine pregnancy test entry visit prior randomization also agreeable use contraceptive choice study period . `` Women reproductive potential '' define woman postmenopausal least 24 consecutive month ( i.e. , menses within precede 24 month ) undergo surgical sterilization ( i.e. , hysterectomy , bilateral oophorectomy , tubal ligation ) 1 . Current CD4+ Tcell count &lt; 200 cells/µL 2 . Current antiretroviral regimen consist three antiretroviral class 3 . History genotypic resistance , phenotypic resistance intolerance either DRV DTG . Prohibited protease mutation : V11I , V32I , L33F , I47V/A/L , I50V , I54T/S/L/M , T74P , L76V , V82F , I84V , L89V Prohibited INSTI mutation : E92Q , E92K/A , G140S/A/C , Q148H/R/K Q148 substitution plus following : L74I/M , E138A/D/K/T , G140A/S , Y143H/R , E157Q , G163E/K/Q/R/S , G193E/R . 4 . History virologic failure INSTI prior study enrollment 5 . Severe hepatic impairment ( Child Pugh Class C ) 6 . Hepatitis B Surface Antigen Positive 7 . Breastfeeding , pregnancy , plan become pregnant study 8 . Known allergy/sensitivity study drug formulation . 9 . Receipt plan receipt prohibit concomitant medication ( See section 5.2.1 ) 10 . Active drug alcohol use dependence , opinion site investigator , would interfere adherence study procedure treatment . 11 . Serious medical illness , opinion site investigator , preclude safe participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>